Drug Trial Radar · NCT04841577
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
Last checked: Nov 20, 2026Latest source record: Sep 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
976
Actual
Start
Apr 27, 2021
Primary completion
Sep 22, 2021
Study completion Feb 8, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the seasonal quadrivalent influenza vaccine (FLU-QIV) in adults aged 60 years and above compared to separate administration of the vaccines.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccineBiological
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
FLU-QIVBiological
FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RSV-A Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMTs)Time frame: At 1 month after the RSV_PreF3 OA investigational vaccine dose (at Day 31 for the Co-Ad Group and at Day 61 for the Control Group)
- Hemagglutinin Inhibition (HI) Antibody Titers for Each of the FLU Vaccine Strains Expressed as Group GMTsTime frame: 1 month after the FLU vaccine dose (at Day 31)
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Auckland, New Zealand
GSK Investigational Site
Auckland, New Zealand
GSK Investigational Site
Christchurch, New Zealand
GSK Investigational Site
Havelock North, New Zealand
GSK Investigational Site
Paraparaumu, New Zealand
GSK Investigational Site
Tauranga, New Zealand
GSK Investigational Site
Wellington, New Zealand
GSK Investigational Site
Panama City, Panama
GSK Investigational Site
Panama City, Panama
GSK Investigational Site
Panama City, Panama
GSK Investigational Site
Panama City, Panama
GSK Investigational Site
Panama City, Panama
GSK Investigational Site
Boksburg, Gauteng, South Africa
GSK Investigational Site
Middelburg, Mpumalanga, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.